Most cases of chronic lymphocytic leukemia (CLL) express surface immunoglobulin (Ig)M and surface IgD at levels lower than normal B cells. IgG-positive CLL is a relatively rare variant of CLL (frequency 6-10%), whose origin and ontogenetic relationship to the common IgM/IgD variant remains unknown.
Important biological and prognostic information in CLL is obtained by cytogenetic analysis. In particular, certain recurrent cytogenetic aberrations in CLL have been associated with different clinical outcomes; for instance, abnormalities of chromosome 17p are associated with poor prognosis, whereas deletions of chromosome 13q are associated with a favorable prognosis. 1 Trisomy 12 is a recurrent chromosomal aberration occurring in 10-20% of CLL that has been associated with an intermediate risk.
1,2 A small percentage, between 1.6 and 5%, of patients with trisomy 12 also have trisomy 19 and may constitute a distinct subgroup. [3] [4] [5] This cytogenetic profile was recently shown to be associated with somatically mutated immunoglobulin heavy variable (IGHV) genes. 4, 5 We here significantly extend previous observations by reporting 20 additional cases with coexisting trisomies of chromosomes 12 and 19, with 18/20 cases expressing mutated IGHV genes and 15/20 cases also exhibiting trisomy 18. Importantly, we also demonstrate that the distinct karyotypic profile þ 12, þ 19 is significantly associated with very high CD38 expression and occurs exclusively in isotype-switched sIgG-positive CLL.
The present study included 968 CLL cases from collaborating institutes in Greece, the UK and Sweden with available karyotypic data from the following: (i) classic G-banding cytogenetics (n ¼ 929); (ii) interphase fluorescence in situ hybridization analysis (n ¼ 766) using probes for chromosome 12 (CEP12, Vysis, Abbott Park, IL, USA) and chromosome 13 (LSI 13q14/D13S319 and LSI 13q34/13S25 Vysis); and, (iii) high-density 250K single nucleotide polymorphism-arrays (39 CLL cases from Sweden, all with trisomy 12). The group of UK cases without trisomy 12 includes only those cases that were confirmed to be non-trisomic by both fluorescence in situ hybridization and karyotype and so does not represent the entire CLL patient population without trisomy 12. Within this combined cohort of 968 cases, we identified a subgroup of 20 cases (2.1%) with coexistence of trisomies of chromosomes 12 and 19 (' þ 12 þ 19' subgroup); the þ 12 þ 19 profile was detected by G-banding cytogenetics or single nucleotide polymorphism-arrays in 15 and 5 cases, respectively (Table 1) . A further 313/968 cases (32.3%) were found to exhibit trisomy 12 yet without coexisting trisomy 19 (' þ 12 non þ 19'); and, finally, 635 cases did not show trisomy 12 ('no þ 12'). The sole criterion for assignment to the two latter subgroups was the presence or absence of trisomy 12, regardless of any other cytogenetic/genomic aberrations.
Demographic, clinical and biological data for the ' þ 12 þ 19' cases are summarized in Table 1 . Interestingly, 15/20 cases exhibiting this cytogenetic profile were also found to carry trisomy 18 (Figure 1 ). Prompted by these findings, we queried the Mitelman Database of Chromosome Aberrations and Table 2 ): 22/62 þ 18 cases displayed a coexisting trisomy 12, and of these 18 were common hits in both queries, that is, exhibited the þ 12 þ 18 þ 19 profile. On these grounds, we propose that the coexistence of trisomies 12 and 19 may define a distinct cytogenetic subgroup of CLL, whereas the emergence of trisomy 18 in such cases likely represents a clonal evolution event, whose high frequency indicates selection due to a clonal advantage. IGHV usage across the ' þ 12 þ 19' subgroup was heterogeneous, although 4/20 cases (20%) were found to utilize the IGHV3-7 gene. No cases with stereotyped heavy complementaritydetermining region 3 (VH CDR3) sequences were recognized. Following the 98% cutoff value of identity to the germline, 18/20 cases (90%) were considered as IGHV mutated, whereas the remainder (2/20 cases, 10%) were considered as IGHV unmutated, albeit with o100% identity to the germline. Statistically significant differences were identified between the three groups regarding mutational status, with a far lower proportion of IGHV-unmutated cases in the ' þ 12 þ 19' subgroup compared with either the ' þ 12 non þ 19' or 'no þ 12' subgroups ( Table 2) . These findings corroborate a previous report that trisomy 19 is associated with mutated IGHV genes. 5 In addition, they strongly indicate that ' þ 12 þ 19' cases should be considered as distinct from the ' þ 12 non þ 19' cases, as overall, they exhibit very different IGHV gene mutational profiles.
Ample evidence that the ' þ 12 þ 19' subgroup is distinctive was obtained by examining the immunophenotypic features of the leukemic clones. We found that the great majority of CLL cases of this subgroup exhibit very high CD38 expression, even when compared with ' þ 12 isolated' cases, who have previously been associated with increased CD38 expression. 2 In particular, with a 30% cutoff value for positivity, 16/19 cases of the present series with available data (84.2%) were considered as CD38 positive; this was significantly higher (Po0.001) than either the ' þ 12 non þ 19' or the 'no þ 12' cases (Table 2) . Additionally, the ' þ 12 þ 19' subgroup was distinctive for a very high median percentage of CD38 þ cells among positive cases (Table 2) . Similar results were also obtained even when using other cutoff values for positivity regarding CD38 expression, that is, 7 or 20%.
From an immunophenotypic perspective, however, perhaps even more distinctive was the fact that all 15 cases with available FACS data were found to express surface IgG without any evidence for a population of IgM/IgD-expressing cells. The remaining five cases were shown to exclusively carry switched, tumor-derived IGHV-D-J-C g transcripts (reverse transcriptase PCR using appropriate IGHV sense and IGHC antisense primers). Therefore, the present study documents for the first time that the ' þ 12 þ 19' cytogenetic profile is exclusive to the rare IgG-switched variant of CLL. The fact that the coexisting trisomies are not detected in the entire neoplastic clone but only in a proportion of CLL cells, as evidenced by the consistent finding of a variable number of normal metaphases (Table 1) , might be taken as indirect evidence for a secondary event occurring in a cell, which has already undergone class switch recombination (although, in principle, normal metaphases could indicate the presence of residual healthy cells). Furthermore, given the low frequency both of trisomy 19 and sIgG expression in CLL, we argue that their simultaneous occurrence is unlikely to be fortuitous.
Recently, trisomy 12 was reported to be associated with a subset of cases expressing stereotypic unmutated IGHV4-39/ IGKV1-39 (1D-39) B cell receptors of the rare IgG-positive variant. 6 Notably, this subset was subsequently shown to be associated with the chromosomal translocation t(14;19)(q32;q13) coexisting with trisomy 12. 7, 8 In such cases, the BCL-3 protooncogene at 19q13 is juxtaposed to the immunoglobulin heavy chain gene locus at 14q32, leading to overexpression of the Table 2 CD38 expression and IGHV gene mutational status in cases assigned to the +12,+19 subgroup ('+12+19') to cases exhibiting trisomy 12 yet without coexisting trisomy 19 ('+12 non +19') and cases negative for trisomy 12 ('no +12') BCL-3 protein with resultant deregulation of the nuclear factor-kB pathway. Although the þ 12, þ 19 profile described here identifies a CLL subgroup distinct from subset 8, especially in terms of the IGHV repertoire and mutational status, the fact that aberrations of chromosome 19 are biased to sIgG-switched CLL might be considered as evidence of genetic evolution along distinctive yet related, likely antigen-driven and B-cell receptormediated, pathways. In the ' þ 12 þ 19' subgroup, the ordered gain of trisomies, often also including trisomy 18, indeed points to a shared genetic 'route' during leukemogenesis and further indicates a common cellular origin for this subset.
Conflict of interest
The authors declare no conflict of interest.
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients In an important minority of patients with chronic myeloid leukaemia (CML) on imatinib therapy, resistance has been observed, in most cases due to selection of cell clone variants that express BCR-ABL mutants with weakened imatinib-binding interactions. As part of efforts to combat resistance, secondgeneration tyrosine kinase inhibitors (TKIs) have been developed that are optimised for binding to mutated, imatinib-resistant BCR-ABL variants (dasatinib and nilotinib). 1,2 However, these drugs also apply selection pressure on BCR-ABL clones and can generate resistance, whereby the spectrum of resistance mutations is distinct from, but can overlap with, that of imatinib. 3, 4 Thus, upon shifting treatment to a new drug, secondary 'escape-mutant' clones of BCR-ABL-positive cells may emerge during treatment to become predominant in the total leukaemic population. In this scenario, heterogeneous cancer cell populations co-exist and undergo both selective and deselective processes upon drug exposure, but may not be eradicated completely even if a single clone achieves dominance. In this study, we evaluate the dynamics of variant BCR-ABL clones upon exposure to second-line drugs. The analysis of imatinib-resistant subjects at transition from first-to second-line TKI appeared particularly attractive for study, as the situation at the initiation of the salvage therapy comprises multiple
